Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

UNITED THERAPEUTICS (UTHR) EBT: 2009-2025

Historic EBT for UNITED THERAPEUTICS (UTHR) over the last 17 years, with Sep 2025 value amounting to $438.0 million.

  • UNITED THERAPEUTICS's EBT rose 12.71% to $438.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 billion, marking a year-over-year increase of 15.89%. This contributed to the annual value of $1.5 billion for FY2024, which is 20.77% up from last year.
  • Per UNITED THERAPEUTICS's latest filing, its EBT stood at $438.0 million for Q3 2025, which was up 7.25% from $408.4 million recorded in Q2 2025.
  • Over the past 5 years, UNITED THERAPEUTICS's EBT peaked at $438.0 million during Q3 2025, and registered a low of $32.5 million during Q1 2021.
  • For the 3-year period, UNITED THERAPEUTICS's EBT averaged around $371.2 million, with its median value being $388.6 million (2024).
  • In the last 5 years, UNITED THERAPEUTICS's EBT slumped by 81.06% in 2021 and then surged by 849.85% in 2022.
  • Quarterly analysis of 5 years shows UNITED THERAPEUTICS's EBT stood at $140.5 million in 2021, then grew by 27.26% to $178.8 million in 2022, then soared by 65.21% to $295.4 million in 2023, then soared by 34.22% to $396.5 million in 2024, then increased by 12.71% to $438.0 million in 2025.
  • Its EBT was $438.0 million in Q3 2025, compared to $408.4 million in Q2 2025 and $423.5 million in Q1 2025.